Beyond PSA: Using proteomics to screen for PCa

During the past decade, serum prostate-specific antigen testing has become widely accepted as a means to improve early detection of prostate cancer. Thousands of studies have been performed to determine the most appropriate use of PSA testing and to improve its accuracy.

Related Content:

Drug Therapy

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria

FDA approves androgen inhibitor for metastatic PCa